Nuclear Medicine and Molecular Imaging

, Volume 53, Issue 4, pp 242–246 | Cite as

Theranostics Based on Liposome: Looking Back and Forward

  • Wooseung Lee
  • Hyung-Jun ImEmail author


Liposome is one of the oldest yet most successful nanomedicine platforms. Doxil®, PEGylated liposome loaded with doxorubicin (DOX), was approved by the FDA in 1995 for the treatment of AIDS-related Kaposi’s sarcoma, and it was the first approval for nanomedicine. Since then, liposome-based therapeutics were approved for the treatment of various diseases and many clinical trials are underway. The success of the liposome-based therapeutics was due to following factors: (1) ease of synthesis, (2) biocompatibility, (3) the ability to load both hydrophilic and hydrophobic agents, and (4) long circulation property after application of polyethylene glycol (PEG). Recently, more functionalities are introduced to liposome platform, which are (1) in vivo imaging probes for optical, magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), (2) pH and temperature-sensitive lipid moiety, and (3) novel agents for photodynamic and photothermal therapies (PDT, PTT). These conventional and newly tested advantages make the liposome to be one of the most promising nanoplatforms for theranostics.


Liposome Theranostics Nanomedicine Controlled drug release 


Funding Information

This study was supported by Research Resettlement Fund for the new faculty of Seoul National University, the National Research Foundation of Korea (NRF) (NRF-2017R1D1A1B03035556 and NRF-2019M2D2A1A01058210), and the Ministry of Health and Welfare Korea (HI18C0886 and HI19C0339).

Compliance with Ethical Standards

Conflict of Interest

Wooseung Lee and Hyung-Jun Im declare that they have no conflict of interest.

Ethical Approval

This work does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

Not applicable.


  1. 1.
    Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics. 2016;6:1336–52.CrossRefGoogle Scholar
  2. 2.
    Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102.CrossRefGoogle Scholar
  3. 3.
    Barenholz Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–34.CrossRefGoogle Scholar
  4. 4.
    Adler-moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993;3:429–50.CrossRefGoogle Scholar
  5. 5.
    Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9.Google Scholar
  6. 6.
    Gardikis K, Tsimplouli C, Dimas K, Micha-Screttas M, Demetzos C. New chimeric advanced drug delivery nano systems (chi-aDDnSs) as doxorubicin carriers. Int J Pharm. 2010;402:231–7.CrossRefGoogle Scholar
  7. 7.
    Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.CrossRefGoogle Scholar
  8. 8.
    Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71:555–64.CrossRefGoogle Scholar
  9. 9.
    Merhav H, Mieles L. Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplant Proc. 1997;29:2670–4.CrossRefGoogle Scholar
  10. 10.
    Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines. 2008;7:1141–50.CrossRefGoogle Scholar
  11. 11.
    Jonas JB. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2002;133:857–9.CrossRefGoogle Scholar
  12. 12.
    Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.CrossRefGoogle Scholar
  13. 13.
    Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115:10938–66.CrossRefGoogle Scholar
  14. 14.
    Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660–8.CrossRefGoogle Scholar
  15. 15.
    Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297–315.CrossRefGoogle Scholar
  16. 16.
    Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–92.Google Scholar
  17. 17.
    Golombek SK, May J-N, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38.CrossRefGoogle Scholar
  18. 18.
    Im HJ, England CG, Feng L, et al. Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated nanoparticles in peripheral arterial disease. ACS Appl Mater Interfaces. 2016;8:17955–63.CrossRefGoogle Scholar
  19. 19.
    Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005;105:305–17.CrossRefGoogle Scholar
  20. 20.
    Xu H, Ye F, Hu M, et al. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv. 2015;22:598–607.CrossRefGoogle Scholar
  21. 21.
    Borresen B, Henriksen JR, Clergeaud G, et al. Theranostic imaging may vaccinate against the therapeutic benefit of long circulating PEGylated liposomes and change cargo pharmacokinetics. ACS Nano. 2018;12:11386–98.CrossRefGoogle Scholar
  22. 22.
    Ishihara T, Maeda T, Sakamoto H, et al. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules. 2010;11:2700–6.CrossRefGoogle Scholar
  23. 23.
    Zhang Q, Deng C, Fu Y, Sun X, Gong T, Zhang Z. Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response. Mol Pharm. 2016;13:1800–8.CrossRefGoogle Scholar
  24. 24.
    Li Y, Liu R, Shi Y, Zhang Z, Zhang X. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon. Theranostics. 2015;5:583–96.CrossRefGoogle Scholar
  25. 25.
    Deissler V, Ruger R, Frank W, Fahr A, Kaiser WA, Hilger I. Fluorescent liposomes as contrast agents for in vivo optical imaging of edemas in mice. Small. 2008;4:1240–6.CrossRefGoogle Scholar
  26. 26.
    Mukthavaram R, Wrasidlo W, Hall D, Kesari S, Makale M. Assembly and targeting of liposomal nanoparticles encapsulating quantum dots. Bioconjug Chem. 2011;22:1638–44.CrossRefGoogle Scholar
  27. 27.
    Tagami T, Foltz WD, Ernsting MJ, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 2011;32:6570–8.CrossRefGoogle Scholar
  28. 28.
    Mikhaylov G, Mikac U, Magaeva AA, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6:594.CrossRefGoogle Scholar
  29. 29.
    Petersen AL, Henriksen JR, Binderup T, et al. In vivo evaluation of PEGylated (6)(4)Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:941–52.CrossRefGoogle Scholar
  30. 30.
    Lee H, Gaddy D, Ventura M, et al. Companion diagnostic (64)Cu-liposome positron emission tomography enables characterization of drug delivery to tumors and predicts response to cancer nanomedicines. Theranostics. 2018;8:2300–12.CrossRefGoogle Scholar
  31. 31.
    Seo JW, Zhang H, Kukis DL, Meares CF, Ferrara KW. A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem. 2008;19:2577–84.CrossRefGoogle Scholar
  32. 32.
    Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int J Rad Appl Instrum B. 1992;19:539–47.CrossRefGoogle Scholar
  33. 33.
    Feng L, Cheng L, Dong Z, et al. Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy. ACS Nano. 2017;11:927–37.CrossRefGoogle Scholar
  34. 34.
    Ma M, Lei M, Tan X, Tan F, Li N. Theranostic liposomes containing conjugated polymer dots and doxorubicin for bio-imaging and targeted therapeutic delivery. RSC Adv. 2016;6:1945–57.CrossRefGoogle Scholar
  35. 35.
    Zhang K, Zhang Y, Meng X, et al. Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy. Biomaterials. 2018;185:301–9.CrossRefGoogle Scholar
  36. 36.
    Rengan AK, Bukhari AB, Pradhan A, et al. In vivo analysis of biodegradable liposome gold nanoparticles as efficient agents for photothermal therapy of Cancer. Nano Lett. 2015;15:842–8.CrossRefGoogle Scholar
  37. 37.
    Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387–98.Google Scholar
  38. 38.
    Demel RA, De Kruyff B. The function of sterols in membranes. Biochim Biophys Acta. 1976;457:109–32.CrossRefGoogle Scholar
  39. 39.
    Yu L, Dong A, Guo R, Yang M, Deng L, Zhang J. DOX/ICG Coencapsulated liposome-coated thermosensitive nanogels for nir-triggered simultaneous drug release and photothermal effect. ACS Biomater Sci Eng. 2018;4:2424–34.CrossRefGoogle Scholar
  40. 40.
    Lai MZ, Duzgunes N, Szoka FC. Effects of replacement of the hydroxyl group of cholesterol and tocopherol on the thermotropic behavior of phospholipid membranes. Biochemistry. 1985;24:1646–53.CrossRefGoogle Scholar
  41. 41.
    Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta. 1995;1238:147–55.CrossRefGoogle Scholar
  42. 42.
    Nayar R, Schroit AJ. Generation of pH-sensitive liposomes: use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine. Biochemistry. 1985;24:5967–71.CrossRefGoogle Scholar
  43. 43.
    Zhao Y, Ren W, Zhong T, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Control Release. 2016;222:56–66.CrossRefGoogle Scholar
  44. 44.
    Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Department of Transdisciplinary Studies, Graduate School of Convergence Science and TechnologySeoul National UniversitySeoulRepublic of Korea

Personalised recommendations